These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21179398)

  • 1. PI3Kα inhibitors that inhibit metastasis.
    Schmidt-Kittler O; Zhu J; Yang J; Liu G; Hendricks W; Lengauer C; Gabelli SB; Kinzler KW; Vogelstein B; Huso DL; Zhou S
    Oncotarget; 2010 Sep; 1(5):339-48. PubMed ID: 21179398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
    Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P3Kα: a driver of tumor metastasis?
    Zawel L
    Oncotarget; 2010 Sep; 1(5):315-316. PubMed ID: 21307397
    [No Abstract]   [Full Text] [Related]  

  • 4. N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα).
    Sabbah DA; Simms NA; Wang W; Dong Y; Ezell EL; Brattain MG; Vennerstrom JL; Zhong HA
    Bioorg Med Chem; 2012 Dec; 20(24):7175-83. PubMed ID: 23121722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
    Dong C; Chen Y; Li H; Yang Y; Zhang H; Ke K; Shi XN; Liu X; Li L; Ma J; Kung HF; Chen C; Lin MC
    Int J Biol Sci; 2019; 15(7):1523-1532. PubMed ID: 31337981
    [No Abstract]   [Full Text] [Related]  

  • 6. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
    Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
    Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
    Yin Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
    Eur J Med Chem; 2019 Nov; 182():111630. PubMed ID: 31446244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
    Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
    Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
    Sabbah DA; Simms NA; Brattain MG; Vennerstrom JL; Zhong H
    Bioorg Med Chem Lett; 2012 Jan; 22(2):876-80. PubMed ID: 22212721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
    Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
    Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
    Nagarajan A; Dogra SK; Sun L; Gandotra N; Ho T; Cai G; Cline G; Kumar P; Cowles RA; Wajapeyee N
    Mol Cell; 2017 Aug; 67(4):685-701.e6. PubMed ID: 28803777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
    Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
    Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
    Martin-Fernandez C; Bales J; Hodgkinson C; Welman A; Welham MJ; Dive C; Morrow CJ
    Mol Cancer Res; 2009 Jun; 7(6):955-65. PubMed ID: 19509113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
    Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
    Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
    Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3Kα inhibitor DFX24 suppresses tumor growth and metastasis in non-small cell lung cancer via ERK inhibition and EPHB6 reactivation.
    Fan YH; Ding HW; Kim D; Liu JY; Hong JY; Xu YN; Wang D; Yang XS; Lee SK
    Pharmacol Res; 2020 Oct; 160():105147. PubMed ID: 32814167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.